StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,400 shares, an increase of 45.5% from the January 15th total of 4,400 shares. Based on an average daily trading volume, of 4,400 shares, the days-to-cover ratio is currently 1.5 days.
StageZero Life Sciences Stock Performance
SZLSF stock traded up $0.00 during midday trading on Monday, hitting $0.05. 1,000 shares of the stock traded hands, compared to its average volume of 6,350. The firm has a market cap of $5.60 million, a P/E ratio of -0.76 and a beta of 0.90. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.08 and a quick ratio of 0.04. The stock's fifty day simple moving average is $0.05 and its 200-day simple moving average is $0.06. StageZero Life Sciences has a 1-year low of $0.04 and a 1-year high of $0.20.
Get StageZero Life Sciences alerts:StageZero Life Sciences Company Profile
(Get Rating)
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.Featured Stories
- Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
- Should Medtronic's Recent Colibri Patent Controversy Concern You?
- Checkpoint Software Helps Cyber Security Stocks Bottom
- Under Armour Stock, Gap and Crap, Here's Why
- Is Chevron Positioned To Take Energy Sector Leadership?
- What Does the Consumer Price Index Measure?
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.